PeptideTracker

177 posts

PeptideTracker banner
PeptideTracker

PeptideTracker

@PepCalc

All-in-one peptide tracker and calculator

Katılım Ekim 2025
56 Takip Edilen35 Takipçiler
Sabitlenmiş Tweet
PeptideTracker
PeptideTracker@PepCalc·
Our peptide tracker and calculator is live on the App Store!
PeptideTracker tweet media
English
2
0
3
245
9th Life
9th Life@_9th_Life_·
Beginner guide to GLP1 peptides: Semaglutide. The Toyota of weight loss peptides. You've definitely heard of Ozempic, this is the one that kicked off the hype. Ozempic and Wegovy are the same molecule, the difference is the use case: Wegovy is FDA approved for weight loss, Ozempic for type 2 diabetes. Most FDA-approved uses of any GLP-1. Both developed by Novo Nordisk. ~15% weight loss at 68 weeks. Widely adopted, gets the job done. Tirzepatide. The Audi of weight loss peptides. Same platform, better biological engineering. Targets two hormones (GLP-1 + GIP). Stronger results, less nausea, better lean mass retention. ~21% weight loss at 72 weeks. FDA approved for chronic weight management, glycemic control in type 2 diabetes, and obstructive sleep apnea. Like semi it has two brand names: Mounjaro for type 2 diabetes, Zepbound for chronic weight management. Once-weekly injection. Made by Eli Lilly. Retatrutide. The Lamborghini of weight loss peptides. First-in-class triple hormone receptor agonist. Targets three hormones (GLP-1 + GIP + glucagon). Burns fat directly on top of appetite suppression. Phase 2 showed 24% at 48 weeks. Phase 3 TRIUMPH-4 just hit an average of 71.2 lbs lost at 68 weeks on the 12mg dose, the highest weight loss ever recorded in an obesity trial. Also lowered systolic BP by 14 mmHg and cut triglycerides, non-HDL cholesterol, and hsCRP. Still in Phase 3, not FDA approved yet. Seven more Phase 3 readouts expected through 2026. Also made by Eli Lilly. What GLP-1, GIP, and glucagon do in the body: GLP-1 -> released by L-cells in your gut when you eat. Tells your brain you're full, tells your pancreas to release insulin, slows stomach emptying. Your natural "I'm done eating" signal. Half-life of about 2 minutes. These peptides were engineered to last days. GIP -> released by K-cells in your gut when you eat. K-cells are specialized sensor cells in the lining of your duodenum and upper small intestine that detect incoming nutrients (glucose, fat, amino acids) and signal the rest of your metabolism that food has arrived. On its own GIP promotes fat storage and barely touches appetite. Paired with GLP-1, the combo amplifies insulin sensitivity, enhances fat oxidation, and improves how your body handles lipids. Glucagon -> released by alpha cells in your pancreas when blood sugar drops, you're fasting, exercising, or eating a high-protein meal. It's the direct counterweight to insulin. Triggers your liver to dump stored glycogen, blocks the liver from storing more, and creates brand new glucose from amino acids and fat (gluconeogenesis). This is what drives the increase in energy expenditure with reta and the direct fat-burning effect. These peptides are injectable versions of hormones your body already makes, just stronger and longer lasting. Practical differences: Semi -> most data behind it, most widely adopted, the Toyota Camry of the category Tirz -> sweet spot for most people, GIP blunts the GI side effects for a smoother ride, the Audi Reta -> strongest, fastest, glucagon adds direct fat burn and better lipid/liver markers, but resting HR bump and side effects more pronounced at high doses, the Lambo How people gain access: Semi and tirz -> Two options. #1: consult a doctor and get the brand or compounded version prescribed. #2: gray market, research labs producing the peptide "not for human consumption." Option 1 you're a patient, option 2 you're a lab rat. Reta -> Lab rat methods only. #1: gray market vendors, where most people are sourcing it since it isn't FDA approved. #2: enroll in an Eli Lilly clinical trial. Either way you're a lab rat. Lilly is building the Lambo, it's just still in R&D. Different metabolic vehicles, different companies, same lot. Each tier adds horsepower, results, and side effect potential.
English
13
24
286
65.1K
PeptideTracker
PeptideTracker@PepCalc·
The biggest mindset shift coming from peptides: many limitations we thought were fixed features of human biology might actually be adjustable through targeted signaling molecules.
English
0
0
1
14
PeptideTracker
PeptideTracker@PepCalc·
Mind boggling how big the TAM for biotech and peptides will become
TBPN@tbpn

"I think what tech people misunderstand is just the size of the TAM in pharma." @zebulgar says capital will rotate into pharma after AGI: "Anthropic is at what, a $60B run rate? Keytruda, the drug that Merck did in 2019, that one drug's topline is $25B in revenue. Just that one drug." "By the way, once there's AGI, what do you think everybody's going to be focused on afterwards? Everybody's just going to want to live forever. Where do you think the capital is going to rotate into? It's going to rotate into longevity, therapeutics, and manufacturing."

English
0
0
1
32
PeptideTracker
PeptideTracker@PepCalc·
Semax and Selank come from Russian research and have developed cult followings for delivering calm focus and mental clarity without the jittery feeling of traditional stimulants.
English
0
0
0
27
PeptideTracker
PeptideTracker@PepCalc·
Insulin is technically peptide. Retatrutide is a synthetic peptide. Your body already produces millions of peptides naturally. The current hype is about using targeted synthetic versions for specific benefits.
English
0
0
1
58
Antonio Linares
Antonio Linares@alc2022·
$HIMS fundamentals are in extraordinary shape All important metrics came in at or near ATHs, with tough YoY comps $HIMS is now a two sided healthcare operating system Still, investors continue to sell their shares at irrationally low prices Thank you very much!
Antonio Linares@alc2022

Everyone called $PLTR a consulting company at $7. I said it was an AI platform being born. AIP came. The rest is history. $HIMS just had its Palantir moment. The numbers look ugly. They are supposed to. This is what a transformation looks like before everyone understands what is being built.

English
37
20
386
56.5K
Kevin Xu
Kevin Xu@kevinxu·
call me crazy but i'm not quite convinced $HIMS ends this down -10%. volume is too low. earnings call in 15 min.
English
145
11
759
166.4K
PeptideTracker
PeptideTracker@PepCalc·
$HIMS with one of the best founders out there @AndrewDudum
andrewdudum@AndrewDudum

2026 is proving to be a defining year at Hims & Hers. More and more, we are the partner people rely on for a simpler, more personal path to feeling great. Our Q1 2026 results are now live and they make it clear that we aren’t just growing. We’re showing the world what happens when you focus on transforming what people believe is possible in healthcare. Here’s what to know from today’s numbers: - We’re building momentum in the US. There are more ways than ever for customers to start – and stay – with Hims & Hers. That’s driving momentum across all of our specialties, especially weight loss, where we’re seeing near-record adoption levels since March. Our strategic shift is paying off. - Our global reach is multiplying our impact. As we expand globally, we’ll bring more data points into our ecosystem and extend the network effects of our platform. This isn’t just good for our customers. It’s good for our partners, too, who are starting to see the potential in a high-touch, personal platform experience designed to help customers stick to their treatment plans longer and achieve their goals better than with medication alone. - We have deeper-than-ever relationships with our customers. We’re moving beyond simply responding to symptoms by investing in areas like diagnostics that make it easier for anyone to feel their best. We’re now a trusted, comprehensive health partner that’s helping customers proactively discover early signs of conditions that may not be symptomatic yet. - Our platform is getting harder to replicate. Our technology and data infrastructure is getting more agile and more intelligent with tens of millions of customer touchpoints. We power the end-to-end customer experience, which means we’re constantly growing a closed-loop, proprietary data flywheel that we believe is unmatched. I’ve never been more confident in the future of health – and I’ve never been more sure that we’re the ones building it. More on this quarter’s results: news.hims.com/newsroom/how-w… Important info here: investors.hims.com/news/news-deta… news.hims.com/disclaimers/di…

English
0
0
0
78